Literature DB >> 21656335

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Ji-Won Lee1, Ayumi Iwahashi, Shin-ichi Hasegawa, Takayuki Yonezawa, Won Bae Jeon, Byung-Yoon Cha, Kazuo Nagai, Je-Tae Woo.   

Abstract

Excessive receptor activator of NF-κB ligand (RANKL) signaling causes enhanced osteoclast formation and bone resorption. The downregulation of RANKL expression and its downstream signals may be an effective therapeutic approach to the treatment of bone loss diseases such as osteoporosis. Here, we found that coptisine, one of the isoquinoline alkaloids from Coptidis Rhizoma, exhibited inhibitory effects on osteoclastogenesis in vitro. Although coptisine has been studied for its antipyretic, antiphotooxidative, dampness dispelling, antidote, antinociceptive, and anti-inflammatory activities in vitro and in vivo, its effects on osteoclastogenesis have not been investigated. Therefore, we evaluated the effects of coptisine on osteoblastic cells as well as osteoclast precursors for osteoclastogenesis in vitro. The addition of coptisine to cocultures of mouse bone marrow cells and primary osteoblastic cells with 10(-8) M 1α,25(OH)(2)D(3) caused significant inhibition of osteoclast formation in a dose-dependent manner. Reverse transcriptase polymerase chain reaction (RT-PCR) analyses revealed that coptisine inhibited RANKL gene expression and stimulated the osteoprotegerin gene expression induced by 1α,25(OH)(2)D(3) in osteoblastic cells. Coptisine strongly inhibited RANKL-induced osteoclast formation when added during the early stage of bone marrow macrophage (BMM) cultures, suggesting that it acts on osteoclast precursors to inhibit RANKL/RANK signaling. Among the RANK signaling pathways, coptisine inhibited NF-κB p65 phosphorylations, which are regulated in response to RANKL in BMMs. Coptisine also inhibited the RANKL-induced expression of NFATc1, which is a key transcription factor. In addition, 10 μM coptisine significantly inhibited both the survival of mature osteoclasts and their pit-forming activity in cocultures. Thus, coptisine has potential for the treatment or prevention of several bone diseases characterized by excessive bone destruction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656335     DOI: 10.1007/s11418-011-0537-7

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  30 in total

1.  Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein.

Authors:  Olivier Destaing; Frédéric Saltel; Jean-Christophe Géminard; Pierre Jurdic; Frédéric Bard
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 3.  Ethnopharmacology and Western medicine.

Authors:  J D Phillipson; L A Anderson
Journal:  J Ethnopharmacol       Date:  1989-02       Impact factor: 4.360

Review 4.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

5.  Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.

Authors:  V Iotsova; J Caamaño; J Loy; Y Yang; A Lewin; R Bravo
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

Authors:  N Udagawa; N Takahashi; H Yasuda; A Mizuno; K Itoh; Y Ueno; T Shinki; M T Gillespie; T J Martin; K Higashio; T Suda
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

7.  Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4.

Authors:  Eun-Ju Chang; Hyon Jong Kim; Jeongim Ha; Hyung Joon Kim; Jiyoon Ryu; Kwang-Hyun Park; Uh-Hyun Kim; Zang Hee Lee; Hyun-Man Kim; David E Fisher; Hong-Hee Kim
Journal:  J Cell Sci       Date:  2006-12-12       Impact factor: 5.285

8.  Generation of osteoclasts in vitro, and assay of osteoclast activity.

Authors:  Naoyuki Takahashi; Nobuyuki Udagawa; Yasuhiro Kobayashi; Tatsuo Suda
Journal:  Methods Mol Med       Date:  2007

9.  The anti-inflammatory potential of berberine in vitro and in vivo.

Authors:  Chi-Li Kuo; Chin-Wen Chi; Tsung-Yun Liu
Journal:  Cancer Lett       Date:  2004-01-20       Impact factor: 8.679

10.  Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.

Authors:  Jin-Ping Hu; Kazuhisa Nishishita; Eiko Sakai; Hajime Yoshida; Yuzo Kato; Takayuki Tsukuba; Kuniaki Okamoto
Journal:  Eur J Pharmacol       Date:  2007-11-17       Impact factor: 4.432

View more
  10 in total

Review 1.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

2.  Coptisine Prevented IL-β-Induced Expression of Inflammatory Mediators in Chondrocytes.

Authors:  Kai Zhou; Li Hu; Wenjun Liao; Defeng Yin; Feng Rui
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

3.  Berberine enhances defects in the establishment of leaf polarity in asymmetric leaves1 and asymmetric leaves2 of Arabidopsis thaliana.

Authors:  Ayami Nakagawa; Hiro Takahashi; Shoko Kojima; Nobuo Sato; Kazuomi Ohga; Byung Yoon Cha; Je-Tae Woo; Kazuo Nagai; Gorou Horiguchi; Hirokazu Tsukaya; Yasunori Machida; Chiyoko Machida
Journal:  Plant Mol Biol       Date:  2012-06-10       Impact factor: 4.076

4.  The importance of the prenyl group in the activities of osthole in enhancing bone formation and inhibiting bone resorption in vitro.

Authors:  Yuan-Kun Zhai; Ya-Lei Pan; Yin-Bo Niu; Chen-Rui Li; Xiang-Long Wu; Wu-Tu Fan; Ting-Li Lu; Qi-Bing Mei; Cory J Xian
Journal:  Int J Endocrinol       Date:  2014-07-24       Impact factor: 3.257

5.  Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway.

Authors:  HaiJing Zhang; GuangMing Song; ZhiHui Zhang; HuaChen Song; XiaoNan Tang; AnJun Deng; WenJie Wang; LianQiu Wu; HaiLin Qin
Journal:  Front Pharmacol       Date:  2017-09-05       Impact factor: 5.810

6.  The promotion function of Berberine for osteogenic differentiation of human periodontal ligament stem cells via ERK-FOS pathway mediated by EGFR.

Authors:  Jin Liu; Xiaodan Zhao; Dandan Pei; Guo Sun; Ye Li; Chunhui Zhu; Cui Qiang; Junyi Sun; Jianfeng Shi; Yan Dong; Jianzhong Gou; Sicen Wang; Ang Li
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

7.  Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis.

Authors:  Ching-Chieh Weng; Pei-Ya Ding; Yu-Hsuan Liu; John R Hawse; Malayannan Subramaniam; Chia-Chen Wu; Yu-Chun Lin; Chiao-Yun Chen; Wen-Chun Hung; Kuang-Hung Cheng
Journal:  Oncogene       Date:  2018-11-22       Impact factor: 9.867

8.  The therapeutic effect of Fufang Zhenshu Tiaozhi (FTZ) on osteoclastogenesis and ovariectomized-induced bone loss: evidence from network pharmacology, molecular docking and experimental validation.

Authors:  Xiaojun Chen; Jiangyan Wang; Lin Tang; Qiuying Ye; Qunwei Dong; Zhangwei Li; Li Hu; Chenghong Ma; Jiake Xu; Ping Sun
Journal:  Aging (Albany NY)       Date:  2022-07-12       Impact factor: 5.955

9.  Potential antiosteoporotic agents from plants: a comprehensive review.

Authors:  Min Jia; Yan Nie; Da-Peng Cao; Yun-Yun Xue; Jie-Si Wang; Lu Zhao; Khalid Rahman; Qiao-Yan Zhang; Lu-Ping Qin
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-31       Impact factor: 2.629

10.  Bioinformatics analysis for the antirheumatic effects of huang-lian-jie-du-tang from a network perspective.

Authors:  Haiyang Fang; Yichuan Wang; Tinghong Yang; Yang Ga; Yi Zhang; Runhui Liu; Weidong Zhang; Jing Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-21       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.